Management will host a conference call to discuss the results and provide an expanded business update as follows: The webcast will be archived under the News & Events section of the Company’s investor ...

The $50.0 million aggregate principal amount of 2030 Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 2030 Notes that were ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement. Full year 2025 revenue of $33.0 million, at the top of the range of ...

Reports new post-hoc analyses from REMAIN-1 Midpoint Cohort showing statistically significant ablation-length (i.e., dose)-dependent treatment effect on post-GLP-1 weight maintenance at 6 months ...

MitoSynergy’s BioCopper1® is formulated to deliver copper directly in its biologically active Copper (I) state, allowing for more efficient cellular uptake and mitochondrial utilization. BioCopper1® ...

Fourth quarter and full year results reflect temporary planned scale back in wholesale production At year-end was back to fully planted with legacy greenhouses and the most overall acreage planted in ...

About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, ...

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX \| TSXV: XRTX \| Frankfurt: ANU), a late-stage clinical ...

Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 Completed 52-week follow-up ...

BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported ...